The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II trial of IMMU-132 (isactuzumab govitecan), an anti-Trop-2-SN-38 antibody drug conjugate (ADC): Results in patients with metastatic gastrointestinal (GI) cancers.
 
Alexander Starodub
No Relationships to Disclose
 
Allyson J. Ocean
No Relationships to Disclose
 
Wells A. Messersmith
No Relationships to Disclose
 
Vincent J. Picozzi
Stock and Other Ownership Interests - Amgen, Abbvie, Johnson and Johnson
Honoraria - Celgene
Research Funding - Fibrogen,Clovis,Immunomedics,Aduro, Theranostics
 
Michael J. Guarino
No Relationships to Disclose
 
Sajeve Samuel Thomas
No Relationships to Disclose
 
Aditya Bardia
No Relationships to Disclose
 
Manish A. Shah
Consulting or Advisory Role - Lilly; Sanofi
Research Funding - Bayer/Onyx (Inst); Genentech (Inst); Sanofi (Inst)
 
Serengulam V. Govindan
Employment - Immunomedics
Stock and Other Ownership Interests - Immunomedics
 
Pius P Maliakal
Employment - Immunomedics
Stock and Other Ownership Interests - Immunomedics
 
William A. Wegener
Employment - Immunomedics
Stock and Other Ownership Interests - Immunomedics
 
Steven A. Hamburger
Employment - Immunomedics
Stock and Other Ownership Interests - Immunomedics
 
Robert M. Sharkey
Employment - Immunomedics
Stock and Other Ownership Interests - Immunomedics
 
David M. Goldenberg
Employment - Immunomedics
Leadership - Immunomedics
Stock and Other Ownership Interests - Immunomedics
Patents, Royalties, Other Intellectual Property - Immunomedics